Abstract
Most cases of cystic fibrosis (CF) are caused by the deletion of a single phenylalanine residue at position 508 of the cystic fibrosis transmembrane conductance regulator (CFTR). The mutant F508del-CFTR is retained in the endoplasmic reticulum and degraded, but can be induced by low temperature incubation (29°C) to traffic to the plasma membrane where it functions as a chloride channel. Here we show that, cardiac glycosides, at nanomolar concentrations, can partially correct the trafficking of F508del-CFTR in human CF bronchial epithelial cells (CFBE41o-) and in an F508del-CFTR mouse model. Comparison of the tran-scriptional profiles obtained with polarized CFBE41o-cells after treatment with ouabain and by lowtemperature has revealed a striking similarity between the two corrector treatments that is not shared with other correctors. In summary, our study shows a novel function of ouabain and its analogs in the regulation of F508del-CFTR trafficking and suggests that com-pounds that mimic this low temperature correction of trafficking will provide new avenues for the development of therapeutics for CF.
Original language | English (US) |
---|---|
Article number | Article 176 |
Journal | Frontiers in Pharmacology |
Volume | 3 OCT |
DOIs | |
State | Published - 2012 |
Funding
Keywords
- CFBE cells
- Cftr
- Connectivity map
- Cystic fibrosis
- Hierarchical clustering
- Microarray
- Quabain
- Trafficking
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology